Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azilsartan for AF Prevention in Hypertension with LVH
NCT05841654Phase 4Unknown
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of azilsartan in Atrial fibrillation (AFib) (2 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: Incidence and burden of atrial fibrillation at 48 weeks. Status: unknown.
02
Drugs
azilsartan
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05841654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841654.